UPDATE: Jefferies Initiates Coverage on Rollins at Buy on Recurring Revenues
May 30, 2013 at 09:44 AM EDT
In a report published on Wednesday, Jefferies analyst Dan Dolev initiated coverage on Rollins (NYSE: ROL ) with a Buy rating and a price target of $28. In the report, Jefferies stated, "Near term, rising healthcare costs may boost roll-ups. Most (50-90%) bed-bug clients are incremental, which can boost cross-selling.
